Clarity Pharmaceuticals Ltd Asset Resilience Ratio
Clarity Pharmaceuticals Ltd asset resilience ratio. Clarity Pharmaceuticals Ltd (CU6) has an Asset Resilience Ratio of 73.99% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Clarity Pharmaceuticals Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Clarity Pharmaceuticals Ltd (2019–2025)
Asset resilience ratio of Clarity Pharmaceuticals Ltd from 2019 to 2025. This chart shows how Clarity Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read Clarity Pharmaceuticals Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Clarity Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Clarity Pharmaceuticals Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$33.37 Million | 13.05% |
| Short-term Investments | AU$155.80 Million | 60.94% |
| Total Liquid Assets | AU$189.17 Million | 73.99% |
Asset Resilience Insights
- Very High Liquidity: Clarity Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 73.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Clarity Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Clarity Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Clarity Pharmaceuticals Ltd Asset Resilience Ratio by Year (2019–2025)
Clarity Pharmaceuticals Ltd asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Clarity Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 65.08% | AU$65.84 Million ≈ $46.59 Million |
AU$101.17 Million ≈ $71.59 Million |
-2.05pp |
| 2024-06-30 | 67.13% | AU$103.80 Million ≈ $73.45 Million |
AU$154.63 Million ≈ $109.41 Million |
-9.65pp |
| 2023-06-30 | 76.78% | AU$59.04 Million ≈ $41.77 Million |
AU$76.90 Million ≈ $54.41 Million |
+14.67pp |
| 2022-06-30 | 62.11% | AU$62.00 Million ≈ $43.87 Million |
AU$99.82 Million ≈ $70.63 Million |
+15.68pp |
| 2021-06-30 | 46.43% | AU$10.50 Million ≈ $7.43 Million |
AU$22.61 Million ≈ $16.00 Million |
+35.46pp |
| 2020-06-30 | 10.97% | AU$1.00 Million ≈ $707.56K |
AU$9.12 Million ≈ $6.45 Million |
-32.67pp |
| 2019-06-30 | 43.65% | AU$4.52 Million ≈ $3.20 Million |
AU$10.36 Million ≈ $7.33 Million |
-- |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic rad… Read more